Short Interest in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Drops By 19.8%

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) was the recipient of a significant decrease in short interest in December. As of December 31st, there was short interest totaling 4,248,996 shares, a decrease of 19.8% from the December 15th total of 5,300,558 shares. Based on an average daily trading volume, of 875,914 shares, the short-interest ratio is presently 4.9 days. Currently, 4.0% of the shares of the company are sold short. Currently, 4.0% of the shares of the company are sold short. Based on an average daily trading volume, of 875,914 shares, the short-interest ratio is presently 4.9 days.

Insider Buying and Selling

In related news, insider Rafael Amado sold 10,787 shares of the firm’s stock in a transaction on Wednesday, December 31st. The shares were sold at an average price of $17.43, for a total transaction of $188,017.41. Following the sale, the insider owned 52,391 shares in the company, valued at approximately $913,175.13. This trade represents a 17.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 4.96% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Zai Lab stock. SG Americas Securities LLC increased its position in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,396 shares of the company’s stock after purchasing an additional 642 shares during the period. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 at the end of the most recent quarter. 41.65% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on ZLAB. Weiss Ratings restated a “sell (d-)” rating on shares of Zai Lab in a research note on Wednesday, October 8th. UBS Group initiated coverage on Zai Lab in a research note on Wednesday, January 7th. They set a “buy” rating and a $35.00 target price for the company. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Zai Lab has a consensus rating of “Moderate Buy” and an average price target of $53.30.

Zai Lab Price Performance

ZLAB stock opened at $18.58 on Monday. The firm has a market capitalization of $2.08 billion, a PE ratio of -9.53 and a beta of 0.83. The business has a 50 day simple moving average of $19.07 and a 200-day simple moving average of $27.89. Zai Lab has a 1 year low of $16.82 and a 1 year high of $44.34.

Zai Lab (NASDAQ:ZLAB) last posted its earnings results on Thursday, November 6th. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.05). Zai Lab had a negative net margin of 46.83% and a negative return on equity of 25.83%. The company had revenue of $116.10 million during the quarter, compared to analyst estimates of $150.24 million. On average, equities research analysts expect that Zai Lab will post -2.58 EPS for the current year.

About Zai Lab

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.